Eczema Market Size to Reach US$ 37.1 Billion by 2034, Impelled by Advancements in Early Detection

Eczema Market Outlook 2024-2034:

The eczema market size reached a value of US$ 16.8 Billion in 2023. Looking forward, the market is expected to reach US$ 37.1 Billion by 2034, exhibiting a growth rate (CAGR) of 7.46% during 2024-2034. The market is driven by the increasing use of non-pharmacotherapy, such as acupuncture, aromatherapy, lifestyle modification, etc., which can improve treatment outcomes in patients. Additionally, the development of targeted therapies and innovative treatments is further propelling the market growth.

Advances in Early Detection and Diagnostic Technologies: Driving the Eczema Market 

The market for eczema is expanding significantly due to advancements in early identification and diagnostic technology, which are also altering the treatment of this chronic skin ailment. Moreover, modern technologies, such as molecular diagnostics, biomarker-based assays, and advanced imaging methods, are being used to supplement traditional diagnostic methods, which are often based on physical examination and patient history. These developments improve patient’s quality of life by allowing for quicker and more accurate detection, particularly in the early phases before severe symptoms manifest. For instance, non-invasive skin biomarker testing can identify inflammatory patterns linked to eczema, offering information on the underlying causes of the condition. Additionally, genetic testing keeps identifying eczema predispositions, enabling early treatment in populations at risk. Furthermore, mobile AI-enabled applications are emerging, allowing people to track their symptoms and receive rapid assessments, boosting early consultation with healthcare providers. In addition to this, the rising emphasis on precision medicine has resulted in the creation of diagnostic systems that enable individualized treatment approaches. These platforms customize medicine based on an individual's disease profile using data from modern diagnostic testing. As a result, medicines improve in efficacy, enhancing patient compliance and lowering the risk of adverse reactions.

Development of Novel Therapies and Pharmacological Treatments: Contributing to Market Expansion

The eczema market is growing significantly due to the introduction of new therapies and pharmaceutical treatments. The market is expanding rapidly as a result of recent developments in medication development and therapy strategies that have created new opportunities for longer-term, more efficient treatment of the illness. Furthermore, biologics and targeted treatments have emerged as significant advancements in the treatment of moderate to severe eczema. Biologics, when compared to conventional topical corticosteroids and emollients, are made to specifically target immune system elements that contribute to the inflammatory response associated with eczema. These treatments, which include monoclonal antibodies, reduce inflammation and improve symptom control by blocking particular cytokines or immunological pathways. For instance, dupilumab was the first biologic to be licensed for eczema. It facilitated the way for the creation of comparable tailored medicines that show promise for individuals with severe conditions. Besides this, new small-molecule drugs and Janus kinase inhibitors are expanding the range of eczema therapy choices. These oral drugs provide a new alternative for patients who might not react well to biologics or topical therapies by interfering with the signaling pathways that contribute to the immune response in eczema. Moreover, the ongoing clinical trials and research into these novel pharmacological agents continue to fuel optimism for more diverse and potent treatment options. Additionally, the safety and effectiveness profiles of current treatments are being improved by developments in drug delivery technologies, such as nanoparticle-based formulations and microneedle patches. These technologies seek to reduce side effects, enhance the skin's ability to absorb active chemicals and give patients more convenient administration options.

Marketed Therapies in Eczema Market

Adbry (Tralokinumab): LEO Pharma 

Adbry (tralokinumab) is a human IgG4 monoclonal antibody that binds to human interleukin13 (IL-13) and blocks its interaction with the IL-13 receptor α1 and α2 subunits. IL-13 is a naturally found cytokine in the type 2 immune response. Tralokinumab reduces the bioactivity of IL-13 by preventing its interaction with the IL-13Rα1/IL-4Rα receptor complex. Tralokinumab suppresses IL-13-induced reactions, which include the release of proinflammatory cytokines, chemokines, and IgE.

Elidel (Pimecrolimus topical): Novartis/Meda

Elidel (pimecrolimus) is a prescription topical cream that treats mild to moderate eczema by preventing the generation of inflammatory cytokines and mediators. Pimecrolimus binds strongly to macrophilin-12 (FKBP-12) and inhibits calcineurin, a calcium-dependent phosphatase. As a result, it prevents T-cell activation by inhibiting the transcription of early cytokines. Pimecrolimus suppresses cytokine generation in human T-cells at nanomolar doses of interleukin-2 and interferon-gamma (Th1), as well as interleukin-4 and interleukin-10 (Th2). Pimecrolimus also inhibits the production of inflammatory cytokines and mediators from mast cells in vitro in response to antigen/lgE stimulation.

Dupixent (Dupilumab) - Regeneron/Sanofi

Dupilumab is an interleukin-4 (IL-4) receptor alpha antagonist that is used to treat eczema. It is a human monoclonal antibody of the immunoglobulin G4 subclass that suppresses IL-4 and interleukin-13 (IL-13) signaling by preferentially binding to the IL-4 receptor alpha subunit, which is shared by both the IL-4 and IL-13 receptors. Dupilumab suppresses IL-4 signaling through the type 1 receptor, as well as IL-4 and IL-13 signaling through the type 2 receptor. Dupilumab blocks the IL-4R alpha subunit, which reduces IL-4 and IL-13 cytokine-induced responses, such as the release of proinflammatory cytokines, chemokines, and immunoglobulin E.

Cibinqo (Abrocitinib): Pfizer

Cibinqo (Abrocitinib) is a kinase inhibitor that treats moderate-to-severe eczema in adults. Cibinqo is an oral small molecule that specifically inhibits Janus kinase 1 (JAK-1). Inhibition of JAK1 is expected to affect numerous cytokines involved in the pathogenesis of the illness, including interleukin (IL)-4, IL-13, IL-31, IL-22, and thymic stromal lymphopoietin.

Rinvoq (Upadacitinib): AbbVie

Rinvoq (Upadacitinib) is an oral Janus kinase 1-selective inhibitor used to treat moderate to severe eczema, including those who have not responded well to previous medications. Rinvoq works by binding to JAK to inhibit the phosphorylation and activation of STATs (signal transducer and activator of transcriptions). This interrupts the pro-inflammatory cytokine signaling pathway.

Emerging Therapies in Eczema Market

ARQ-252: Arcutis Inc

ARQ-252 is a selective, highly powerful, topical, small-molecule JAK1 inhibitor that is being studied for the treatment of chronic hand eczema. It is a topical cream that functions by suppressing JAK1, an enzyme that plays an important role in the immunological system. ARQ-252 differs from other topical JAK inhibitors in its strong efficacy and very high selectivity against JAK1 over JAK2.

Amlitelimab: Kymab/Sanofi

Amlitelimab, a monoclonal antibody manufactured by Kymab and Sanofi, treats inflammatory conditions and immunological-mediated illnesses such as atopic dermatitis by inhibiting OX40-Ligand, a crucial immune regulator. Amlitelimab interacts with OX40L on antigen-presenting cells (APCs), inhibiting its interaction with OX40 on activated T cells. This aims to reestablish the balance of pro-inflammatory and regulatory T cells. By blocking the OX40-OX40L interaction, Amlitelimab efficiently downregulates the hyperactive immune response, lowering inflammation and tissue damage.

Lebrikizumab: Eli Lilly

Lebrikizumab is an IgG4 monoclonal antibody against IL-13 that treats moderate-to-severe eczema in adults and adolescents. Lebrikizumab selectively inhibits IL-13 signaling via the IL-4Rα/IL-13Rα1 heterodimer, reducing its downstream effects. It binds to IL-13 with high affinity. Inhibiting IL-13 signaling is likely to be beneficial in disorders where IL-13 is a critical contribution to the disease pathogenesis.

Si-544: selectION

si-544 is under clinical development by SelectION for the treatment of eczema. It works by targeting the potassium voltage-gated channel subfamily A member 3 (Kv1.3). It was also being developed for the treatment of vasculitis and psoriasis. si-544 is a potent immuno-selective medication that addresses an important unmet medical need by effectively suppressing and destroying disease-specific, chronically activated TEM cells while retaining complete immunocompetence. The drug is delivered by the subcutaneous method.

KHK 4083: Kyowa Kirin

KHK 4083 is a completely human monoclonal antibody against OX40 that has been designed utilizing Kyowa Kirin's unique POTELLIGENT defucosylation technology to increase antibody-dependent cellular cytotoxicity (ADCC). KHK 4083 targets and inhibits the function of the OX40 receptor expressed on the surface of activated effector T-cells, and it has been shown to promote ADCC-mediated depletion of activated OX40+ T-cells. It has been observed that effector T-cells expressing OX40 are found in atopic dermatitis lesions and play an important role in the disease's pathogenesis.

Detailed list of emerging therapies in Eczema is provided in the final report.

Leading Companies in the Eczema Market:

The market research report by IMARC encompasses a comprehensive analysis of the competitive landscape in the market. Across the global eczema market, several leading companies are at the forefront of developing integrated platforms to enhance the management of eczema. Some of the major players include LEO Pharma, Sanofi, and Pfizer. These companies are driving innovation in the eczema market through continuous research, diagnostic tools, and expanding their product offerings to meet the growing demand for treating the ailment.

In October 2024, LEO Pharma Inc. announced the final results of the five-year extension study ECZTEND, which demonstrated the long-term safety and efficacy profile of Adbry (tralokinumab-ldrm) in adults and adolescents (aged 12 and up) with moderate-to-severe atopic dermatitis. Long-term treatment with tralokinumab-ldrm showed continued efficacy for up to six years. In 92.9% of patients, the Eczema Area and Severity Index (EASI-75) decreased by at least 75% between baseline and Week 248.

In January 2024, Sanofi announced that the U.S. FDA had revised the label for Dupixent (dupilumab) in atopic dermatitis, adding effectiveness and safety data for patients aged 12 and up with uncontrolled moderate-to-severe hand and/or foot involvement. These Phase 3 data result from the first and only trial testing a biologic, especially for this difficult-to-treat population. They have also been added to the Dupixent label in the European Union, with regulatory filings underway in other countries.

In February 2023, Pfizer Inc. announced that the FDA had approved its supplemental New Drug Application (sNDA) for CIBINQO (abrocitinib), extending its indication to include adolescents (12 to <18 years) with refractory, moderate-to-severe atopic dermatitis who are not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is not recommended.

Key Players in Eczema Market:

The key players in the Eczema market who are in different phases of developing different therapies are LEO Pharma, Novartis, Meda, Regeneron, Sanofi, Pfizer, AbbVie, Arcutis Inc, Kymab, Eli Lilly, selection, Kyowa Kirin, and Others.

Regional Analysis:

The major markets for eczema include the United States, Germany, France, the United Kingdom, Italy, Spain, and Japan. According to projections by IMARC, the United States has the largest patient pool for eczema while also representing the biggest market for its treatment. This can be attributed to the rising awareness about eczema and its impact on quality of life, which has led to more individuals seeking medical advice.

Moreover, numerous innovative therapy alternatives, including biologics and JAK inhibitors, are also driving market expansion. These innovative medicines provide more targeted and effective treatments for moderate to severe eczema, broadening the variety of treatment options beyond typical topical therapy. The robust healthcare infrastructure and regulatory environment in the United States facilitate the research and commercialization of innovative medicines, hence accelerating their uptake.

Besides this, health insurance coverage and reimbursement regulations for newer, more expensive treatments make complicated therapies more accessible to a larger patient group. Furthermore, increased consumer interest in over-the-counter skincare products specifically designed for eczema contributes to market growth as awareness and demand for such products rise.

Recent Developments in Eczema Market:

• In October 2024, Eli Lilly and Company announced new results suggesting that EBGLYSS (lebrikizumab-lbkz) improved skin (including the hands and face) and itch in individuals with moderate-to-severe atopic dermatitis (eczema) who had previously had dupilumab. Patients in this trial reported improvements in difficult-to-treat areas after being treated with EBGLYSS. At Week 24, more than half of patients (52 percent) treated with EBGLYSS had clean or nearly clear face dermatitis (F-IGA 0,1 with a decrease of at least two points from baseline). At Week 24, patients with moderate-to-severe hand dermatitis (classified as ≥12) experienced a 75% drop in their modified total lesion symptom score.
• In April 2024, selectION reported positive results from the first-in-human Phase 1b trial of its lead drug, si-544, in patients with atopic dermatitis. The completed Phase 1b trial was a multi-center, double-blind, placebo-controlled evaluation of patients with mild to severe atopic dermatitis. The experiment was aimed to assess the safety, tolerability, and efficacy of si-544.
• In March 2024, Sanofi published positive findings from part 2 of the investigational amlitelimab Phase 2b study STREAM-AD, which indicated sustained improvement of signs and symptoms in individuals with moderate to severe atopic dermatitis who had previously responded to amlitelimab and continued treatment. Additionally, participants who were removed from amlitelimab had a high response rate. The safety profile remained consistent with the first part of the study, with amlitelimab being well tolerated and no new safety concerns detected.

Key information covered in the report

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the eczema market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the eczema market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report offers a comprehensive analysis of current eczema marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

 Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. Across the six major continents and 100+ countries, we work alongside our business partners as one team with a common ambition to achieve unparallelled results, gain a competitive edge, and transform industries. IMARC Group excels in understanding its clients’ business priorities and delivering tailored solutions that drive meaningful outcomes. Our client base spans over 3,000 organizations in the private, public, and social sectors, ranging from high-growth startups to Fortune 500 companies.

Contact US

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Phone Number: - +1 631 791 1145, +91-120-433-0800